Dipeptidyl peptidase-4 inhibitors reduce the incidence of first cardiovascular events in Japanese diabetic patients
Background Dipeptidyl Peptidase-4 (DPP-4) inhibitors do not suppress cardiovascular events in diabetic patients with a history of cardiovascular disease. However, the effect of DPP-4 inhibitors on cardiovascular events in Japanese diabetic patients is unclear. Therefore, we investigated whether DPP-...
Gespeichert in:
| Veröffentlicht in: | Heart and vessels 2023-11, Vol.38 (11), p.1371-1379 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1379 |
|---|---|
| container_issue | 11 |
| container_start_page | 1371 |
| container_title | Heart and vessels |
| container_volume | 38 |
| creator | Soejima, Hirofumi Ogawa, Hisao Morimoto, Takeshi Okada, Sadanori Matsumoto, Chisa Nakayama, Masafumi Masuda, Izuru Jinnouchi, Hideaki Waki, Masako Saito, Yoshihiko |
| description | Background
Dipeptidyl Peptidase-4 (DPP-4) inhibitors do not suppress cardiovascular events in diabetic patients with a history of cardiovascular disease. However, the effect of DPP-4 inhibitors on cardiovascular events in Japanese diabetic patients is unclear. Therefore, we investigated whether DPP-4 inhibitors alter the incidence of cardiovascular events in Japanese diabetic patients without a history of cardiovascular events.
Methods
The Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial was a multicenter, prospective, randomized, open label, blinded, end-point study conducted from 2002 to 2008. After completion of the JPAD trial, we followed up the patients until 2019. Patients who had had a cardiovascular event by the 2013 follow-up were excluded from the study. JPAD patients were divided into a DPP-4 group and a non-DPP-4 group based on whether they were taking DPP-4 inhibitors at the 2013 follow-up because few patients took DPP-4 inhibitors before 2013. We investigated the incidence of cardiovascular events consisting of coronary events, cerebrovascular events, heart failure requiring hospitalization, and aortic and peripheral vascular disease in 1099 JPAD patients until 2019.
Results
During the observation period from 2013 to 2019, 37 (7%) first cardiovascular events occurred in the DPP-4 group (n = 518) and 66 (11%) in the non-DPP-4 group (n = 581). The incidence of cardiovascular events was significantly lower in the DPP-4 group than in the non-DPP-4 group (Log-Rank P = 0.0065). Cox proportional hazards model analysis revealed that the use of DPP-4 inhibitors (hazard ratio 0.65; 95% confidence interval 0.43–0.98; P = 0.038) was an independent factor after adjustment for age ≥ 65 years, hypertension, statin usage, and insulin usage.
Conclusions
Our findings have demonstrated that the use of DPP-4 inhibitors may be associated with a reduced incidence of first cardiovascular events in Japanese diabetic patients. The results require confirmation in randomized controlled trials. |
| doi_str_mv | 10.1007/s00380-023-02291-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2844095025</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2868759778</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-b0a122bd53d67a988b8fa5205311d32641bfd1a426244bb24c3c1bb8d51d64643</originalsourceid><addsrcrecordid>eNp9kUtv1TAQhS0EopfCH2CBLLHpJq2fibNEbYFWldjA2vJjQl3lJsHjVOq_ry8pILHowhp75pvjIx1C3nN2yhnrzpAxaVjDhKxH9LxRL8iOt1w3QnfyJdmxnrPGSNEdkTeId4xx3fP-NTmSna4LTOwIXqQFlpLiw0i3i0NoFE3TbfKpzBlphrgGoOUWajekCFN9zQMdUsZCg8sxzfcOwzq6TOEepoIVpNducRMg0Jich5ICXVxJh-lb8mpwI8K7p3pMfny-_H7-tbn59uXq_NNNE6q_0njmuBA-ahnbzvXGeDM4LZiWnEcpWsX9ELlTohVKeS9UkIF7b6LmsVWtksfkZNNd8vxrBSx2nzDAOFZf84pWGKVYr5nQFf34H3o3r3mq7irVmk73XWcqJTYq5Bkxw2CXnPYuP1jO7CESu0ViayT2dyT24OLDk_Tq9xD_rvzJoAJyA7COpp-Q__39jOwjuhmXKw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2868759778</pqid></control><display><type>article</type><title>Dipeptidyl peptidase-4 inhibitors reduce the incidence of first cardiovascular events in Japanese diabetic patients</title><source>SpringerLink Journals - AutoHoldings</source><creator>Soejima, Hirofumi ; Ogawa, Hisao ; Morimoto, Takeshi ; Okada, Sadanori ; Matsumoto, Chisa ; Nakayama, Masafumi ; Masuda, Izuru ; Jinnouchi, Hideaki ; Waki, Masako ; Saito, Yoshihiko</creator><creatorcontrib>Soejima, Hirofumi ; Ogawa, Hisao ; Morimoto, Takeshi ; Okada, Sadanori ; Matsumoto, Chisa ; Nakayama, Masafumi ; Masuda, Izuru ; Jinnouchi, Hideaki ; Waki, Masako ; Saito, Yoshihiko ; JPAD Trial Investigators ; for the JPAD Trial Investigators</creatorcontrib><description>Background
Dipeptidyl Peptidase-4 (DPP-4) inhibitors do not suppress cardiovascular events in diabetic patients with a history of cardiovascular disease. However, the effect of DPP-4 inhibitors on cardiovascular events in Japanese diabetic patients is unclear. Therefore, we investigated whether DPP-4 inhibitors alter the incidence of cardiovascular events in Japanese diabetic patients without a history of cardiovascular events.
Methods
The Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial was a multicenter, prospective, randomized, open label, blinded, end-point study conducted from 2002 to 2008. After completion of the JPAD trial, we followed up the patients until 2019. Patients who had had a cardiovascular event by the 2013 follow-up were excluded from the study. JPAD patients were divided into a DPP-4 group and a non-DPP-4 group based on whether they were taking DPP-4 inhibitors at the 2013 follow-up because few patients took DPP-4 inhibitors before 2013. We investigated the incidence of cardiovascular events consisting of coronary events, cerebrovascular events, heart failure requiring hospitalization, and aortic and peripheral vascular disease in 1099 JPAD patients until 2019.
Results
During the observation period from 2013 to 2019, 37 (7%) first cardiovascular events occurred in the DPP-4 group (n = 518) and 66 (11%) in the non-DPP-4 group (n = 581). The incidence of cardiovascular events was significantly lower in the DPP-4 group than in the non-DPP-4 group (Log-Rank P = 0.0065). Cox proportional hazards model analysis revealed that the use of DPP-4 inhibitors (hazard ratio 0.65; 95% confidence interval 0.43–0.98; P = 0.038) was an independent factor after adjustment for age ≥ 65 years, hypertension, statin usage, and insulin usage.
Conclusions
Our findings have demonstrated that the use of DPP-4 inhibitors may be associated with a reduced incidence of first cardiovascular events in Japanese diabetic patients. The results require confirmation in randomized controlled trials.</description><identifier>ISSN: 0910-8327</identifier><identifier>EISSN: 1615-2573</identifier><identifier>DOI: 10.1007/s00380-023-02291-4</identifier><identifier>PMID: 37522902</identifier><language>eng</language><publisher>Tokyo: Springer Japan</publisher><subject>Aorta ; Arteriosclerosis ; Aspirin ; Atherosclerosis ; Biomedical Engineering and Bioengineering ; Cardiac Surgery ; Cardiology ; Cardiovascular diseases ; Clinical trials ; Congestive heart failure ; Diabetes ; Diabetes mellitus ; Health hazards ; Hypertension ; Inhibitors ; Insulin ; Medicine ; Medicine & Public Health ; Original Article ; Peptidases ; Statistical models ; Vascular diseases ; Vascular Surgery</subject><ispartof>Heart and vessels, 2023-11, Vol.38 (11), p.1371-1379</ispartof><rights>Springer Nature Japan KK, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. Springer Nature Japan KK, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-b0a122bd53d67a988b8fa5205311d32641bfd1a426244bb24c3c1bb8d51d64643</citedby><cites>FETCH-LOGICAL-c375t-b0a122bd53d67a988b8fa5205311d32641bfd1a426244bb24c3c1bb8d51d64643</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00380-023-02291-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00380-023-02291-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37522902$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soejima, Hirofumi</creatorcontrib><creatorcontrib>Ogawa, Hisao</creatorcontrib><creatorcontrib>Morimoto, Takeshi</creatorcontrib><creatorcontrib>Okada, Sadanori</creatorcontrib><creatorcontrib>Matsumoto, Chisa</creatorcontrib><creatorcontrib>Nakayama, Masafumi</creatorcontrib><creatorcontrib>Masuda, Izuru</creatorcontrib><creatorcontrib>Jinnouchi, Hideaki</creatorcontrib><creatorcontrib>Waki, Masako</creatorcontrib><creatorcontrib>Saito, Yoshihiko</creatorcontrib><creatorcontrib>JPAD Trial Investigators</creatorcontrib><creatorcontrib>for the JPAD Trial Investigators</creatorcontrib><title>Dipeptidyl peptidase-4 inhibitors reduce the incidence of first cardiovascular events in Japanese diabetic patients</title><title>Heart and vessels</title><addtitle>Heart Vessels</addtitle><addtitle>Heart Vessels</addtitle><description>Background
Dipeptidyl Peptidase-4 (DPP-4) inhibitors do not suppress cardiovascular events in diabetic patients with a history of cardiovascular disease. However, the effect of DPP-4 inhibitors on cardiovascular events in Japanese diabetic patients is unclear. Therefore, we investigated whether DPP-4 inhibitors alter the incidence of cardiovascular events in Japanese diabetic patients without a history of cardiovascular events.
Methods
The Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial was a multicenter, prospective, randomized, open label, blinded, end-point study conducted from 2002 to 2008. After completion of the JPAD trial, we followed up the patients until 2019. Patients who had had a cardiovascular event by the 2013 follow-up were excluded from the study. JPAD patients were divided into a DPP-4 group and a non-DPP-4 group based on whether they were taking DPP-4 inhibitors at the 2013 follow-up because few patients took DPP-4 inhibitors before 2013. We investigated the incidence of cardiovascular events consisting of coronary events, cerebrovascular events, heart failure requiring hospitalization, and aortic and peripheral vascular disease in 1099 JPAD patients until 2019.
Results
During the observation period from 2013 to 2019, 37 (7%) first cardiovascular events occurred in the DPP-4 group (n = 518) and 66 (11%) in the non-DPP-4 group (n = 581). The incidence of cardiovascular events was significantly lower in the DPP-4 group than in the non-DPP-4 group (Log-Rank P = 0.0065). Cox proportional hazards model analysis revealed that the use of DPP-4 inhibitors (hazard ratio 0.65; 95% confidence interval 0.43–0.98; P = 0.038) was an independent factor after adjustment for age ≥ 65 years, hypertension, statin usage, and insulin usage.
Conclusions
Our findings have demonstrated that the use of DPP-4 inhibitors may be associated with a reduced incidence of first cardiovascular events in Japanese diabetic patients. The results require confirmation in randomized controlled trials.</description><subject>Aorta</subject><subject>Arteriosclerosis</subject><subject>Aspirin</subject><subject>Atherosclerosis</subject><subject>Biomedical Engineering and Bioengineering</subject><subject>Cardiac Surgery</subject><subject>Cardiology</subject><subject>Cardiovascular diseases</subject><subject>Clinical trials</subject><subject>Congestive heart failure</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Health hazards</subject><subject>Hypertension</subject><subject>Inhibitors</subject><subject>Insulin</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Article</subject><subject>Peptidases</subject><subject>Statistical models</subject><subject>Vascular diseases</subject><subject>Vascular Surgery</subject><issn>0910-8327</issn><issn>1615-2573</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kUtv1TAQhS0EopfCH2CBLLHpJq2fibNEbYFWldjA2vJjQl3lJsHjVOq_ry8pILHowhp75pvjIx1C3nN2yhnrzpAxaVjDhKxH9LxRL8iOt1w3QnfyJdmxnrPGSNEdkTeId4xx3fP-NTmSna4LTOwIXqQFlpLiw0i3i0NoFE3TbfKpzBlphrgGoOUWajekCFN9zQMdUsZCg8sxzfcOwzq6TOEepoIVpNducRMg0Jich5ICXVxJh-lb8mpwI8K7p3pMfny-_H7-tbn59uXq_NNNE6q_0njmuBA-ahnbzvXGeDM4LZiWnEcpWsX9ELlTohVKeS9UkIF7b6LmsVWtksfkZNNd8vxrBSx2nzDAOFZf84pWGKVYr5nQFf34H3o3r3mq7irVmk73XWcqJTYq5Bkxw2CXnPYuP1jO7CESu0ViayT2dyT24OLDk_Tq9xD_rvzJoAJyA7COpp-Q__39jOwjuhmXKw</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Soejima, Hirofumi</creator><creator>Ogawa, Hisao</creator><creator>Morimoto, Takeshi</creator><creator>Okada, Sadanori</creator><creator>Matsumoto, Chisa</creator><creator>Nakayama, Masafumi</creator><creator>Masuda, Izuru</creator><creator>Jinnouchi, Hideaki</creator><creator>Waki, Masako</creator><creator>Saito, Yoshihiko</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20231101</creationdate><title>Dipeptidyl peptidase-4 inhibitors reduce the incidence of first cardiovascular events in Japanese diabetic patients</title><author>Soejima, Hirofumi ; Ogawa, Hisao ; Morimoto, Takeshi ; Okada, Sadanori ; Matsumoto, Chisa ; Nakayama, Masafumi ; Masuda, Izuru ; Jinnouchi, Hideaki ; Waki, Masako ; Saito, Yoshihiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-b0a122bd53d67a988b8fa5205311d32641bfd1a426244bb24c3c1bb8d51d64643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Aorta</topic><topic>Arteriosclerosis</topic><topic>Aspirin</topic><topic>Atherosclerosis</topic><topic>Biomedical Engineering and Bioengineering</topic><topic>Cardiac Surgery</topic><topic>Cardiology</topic><topic>Cardiovascular diseases</topic><topic>Clinical trials</topic><topic>Congestive heart failure</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Health hazards</topic><topic>Hypertension</topic><topic>Inhibitors</topic><topic>Insulin</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Article</topic><topic>Peptidases</topic><topic>Statistical models</topic><topic>Vascular diseases</topic><topic>Vascular Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soejima, Hirofumi</creatorcontrib><creatorcontrib>Ogawa, Hisao</creatorcontrib><creatorcontrib>Morimoto, Takeshi</creatorcontrib><creatorcontrib>Okada, Sadanori</creatorcontrib><creatorcontrib>Matsumoto, Chisa</creatorcontrib><creatorcontrib>Nakayama, Masafumi</creatorcontrib><creatorcontrib>Masuda, Izuru</creatorcontrib><creatorcontrib>Jinnouchi, Hideaki</creatorcontrib><creatorcontrib>Waki, Masako</creatorcontrib><creatorcontrib>Saito, Yoshihiko</creatorcontrib><creatorcontrib>JPAD Trial Investigators</creatorcontrib><creatorcontrib>for the JPAD Trial Investigators</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Heart and vessels</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soejima, Hirofumi</au><au>Ogawa, Hisao</au><au>Morimoto, Takeshi</au><au>Okada, Sadanori</au><au>Matsumoto, Chisa</au><au>Nakayama, Masafumi</au><au>Masuda, Izuru</au><au>Jinnouchi, Hideaki</au><au>Waki, Masako</au><au>Saito, Yoshihiko</au><aucorp>JPAD Trial Investigators</aucorp><aucorp>for the JPAD Trial Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dipeptidyl peptidase-4 inhibitors reduce the incidence of first cardiovascular events in Japanese diabetic patients</atitle><jtitle>Heart and vessels</jtitle><stitle>Heart Vessels</stitle><addtitle>Heart Vessels</addtitle><date>2023-11-01</date><risdate>2023</risdate><volume>38</volume><issue>11</issue><spage>1371</spage><epage>1379</epage><pages>1371-1379</pages><issn>0910-8327</issn><eissn>1615-2573</eissn><abstract>Background
Dipeptidyl Peptidase-4 (DPP-4) inhibitors do not suppress cardiovascular events in diabetic patients with a history of cardiovascular disease. However, the effect of DPP-4 inhibitors on cardiovascular events in Japanese diabetic patients is unclear. Therefore, we investigated whether DPP-4 inhibitors alter the incidence of cardiovascular events in Japanese diabetic patients without a history of cardiovascular events.
Methods
The Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial was a multicenter, prospective, randomized, open label, blinded, end-point study conducted from 2002 to 2008. After completion of the JPAD trial, we followed up the patients until 2019. Patients who had had a cardiovascular event by the 2013 follow-up were excluded from the study. JPAD patients were divided into a DPP-4 group and a non-DPP-4 group based on whether they were taking DPP-4 inhibitors at the 2013 follow-up because few patients took DPP-4 inhibitors before 2013. We investigated the incidence of cardiovascular events consisting of coronary events, cerebrovascular events, heart failure requiring hospitalization, and aortic and peripheral vascular disease in 1099 JPAD patients until 2019.
Results
During the observation period from 2013 to 2019, 37 (7%) first cardiovascular events occurred in the DPP-4 group (n = 518) and 66 (11%) in the non-DPP-4 group (n = 581). The incidence of cardiovascular events was significantly lower in the DPP-4 group than in the non-DPP-4 group (Log-Rank P = 0.0065). Cox proportional hazards model analysis revealed that the use of DPP-4 inhibitors (hazard ratio 0.65; 95% confidence interval 0.43–0.98; P = 0.038) was an independent factor after adjustment for age ≥ 65 years, hypertension, statin usage, and insulin usage.
Conclusions
Our findings have demonstrated that the use of DPP-4 inhibitors may be associated with a reduced incidence of first cardiovascular events in Japanese diabetic patients. The results require confirmation in randomized controlled trials.</abstract><cop>Tokyo</cop><pub>Springer Japan</pub><pmid>37522902</pmid><doi>10.1007/s00380-023-02291-4</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0910-8327 |
| ispartof | Heart and vessels, 2023-11, Vol.38 (11), p.1371-1379 |
| issn | 0910-8327 1615-2573 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2844095025 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Aorta Arteriosclerosis Aspirin Atherosclerosis Biomedical Engineering and Bioengineering Cardiac Surgery Cardiology Cardiovascular diseases Clinical trials Congestive heart failure Diabetes Diabetes mellitus Health hazards Hypertension Inhibitors Insulin Medicine Medicine & Public Health Original Article Peptidases Statistical models Vascular diseases Vascular Surgery |
| title | Dipeptidyl peptidase-4 inhibitors reduce the incidence of first cardiovascular events in Japanese diabetic patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A35%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dipeptidyl%20peptidase-4%20inhibitors%20reduce%20the%20incidence%20of%20first%20cardiovascular%20events%20in%20Japanese%20diabetic%20patients&rft.jtitle=Heart%20and%20vessels&rft.au=Soejima,%20Hirofumi&rft.aucorp=JPAD%20Trial%20Investigators&rft.date=2023-11-01&rft.volume=38&rft.issue=11&rft.spage=1371&rft.epage=1379&rft.pages=1371-1379&rft.issn=0910-8327&rft.eissn=1615-2573&rft_id=info:doi/10.1007/s00380-023-02291-4&rft_dat=%3Cproquest_cross%3E2868759778%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2868759778&rft_id=info:pmid/37522902&rfr_iscdi=true |